- Home
- ALXO vs KUKE Comparison
ALXO vs KUKE Comparison
Compare ALXO & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- KUKE
- Stock Information
- Founded
- ALXO 2015
- KUKE 2002
- Country
- ALXO United States
- KUKE China
- Employees
- ALXO N/A
- KUKE N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- ALXO Health Care
- KUKE Real Estate
- Exchange
- ALXO Nasdaq
- KUKE Nasdaq
- Market Cap
- ALXO 24.0M
- KUKE 30.4M
- IPO Year
- ALXO 2020
- KUKE 2021
- Fundamental
- Price
- ALXO $0.56
- KUKE $3.15
- Analyst Decision
- ALXO Strong Buy
- KUKE
- Analyst Count
- ALXO 6
- KUKE 0
- Target Price
- ALXO $3.30
- KUKE N/A
- AVG Volume (30 Days)
- ALXO 456.6K
- KUKE 8.7K
- Earning Date
- ALXO 05-08-2025
- KUKE 06-10-2025
- Dividend Yield
- ALXO N/A
- KUKE N/A
- EPS Growth
- ALXO N/A
- KUKE N/A
- EPS
- ALXO N/A
- KUKE N/A
- Revenue
- ALXO N/A
- KUKE $9,442,397.00
- Revenue This Year
- ALXO N/A
- KUKE N/A
- Revenue Next Year
- ALXO N/A
- KUKE N/A
- P/E Ratio
- ALXO N/A
- KUKE N/A
- Revenue Growth
- ALXO N/A
- KUKE N/A
- 52 Week Low
- ALXO $0.41
- KUKE $1.45
- 52 Week High
- ALXO $10.97
- KUKE $33.60
- Technical
- Relative Strength Index (RSI)
- ALXO 59.08
- KUKE 33.38
- Support Level
- ALXO $0.44
- KUKE $3.21
- Resistance Level
- ALXO $0.48
- KUKE $3.43
- Average True Range (ATR)
- ALXO 0.05
- KUKE 0.22
- MACD
- ALXO 0.02
- KUKE -0.14
- Stochastic Oscillator
- ALXO 99.16
- KUKE 4.40
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.